Ratings Paragon 28, Inc.

Equities

FNA

US69913P1057

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
7.75 ^USD	-6.06%		-26.40%	-37.65%

May. 09	Piper Sandler Adjusts Price Target on Paragon 28 to $15 From $18, Maintains Overweight Rating	MT
May. 08	Transcript : Paragon 28, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PARAGON 28, INC.	-37.65%	643M	-
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B	A
DEXCOM, INC.	+2.39%	50.53B	B-
CENCORA, INC.	+9.36%	44.8B	B-
HOYA CORPORATION	+2.70%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes